Sign In
Buy FBLG
$0.750
-0.0552 (-6.85%)
At Close: Jun 23, 2026
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
08:30am, Monday, 22'nd Jun 2026
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers Allowed claims directly support the Company's ongoing Phase 1/2 clinical
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
08:30am, Tuesday, 16'th Jun 2026
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
07:00am, Wednesday, 03'rd Jun 2026
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
06:46am, Wednesday, 03'rd Jun 2026
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease In animal studies, human
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
08:30am, Monday, 18'th May 2026
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
08:30am, Monday, 11'th May 2026
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated
FibroBiologics CEO Issues Letter to Shareholders
08:30am, Tuesday, 05'th May 2026
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the de
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
08:30am, Monday, 04'th May 2026
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the de
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
05:55pm, Thursday, 30'th Apr 2026
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
08:30am, Thursday, 30'th Apr 2026
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
FibroBiologics Compliant with All Nasdaq Listing Requirements
04:01pm, Monday, 20'th Apr 2026
HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced vaccine efficacy Preclinical models
FibroBiologics Announces Closing of $3 Million Public Offering
04:01pm, Thursday, 02'nd Apr 2026
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending
